NCT01430104View on ClinicalTrials.gov

A Study of Teriparatide in Japanese Osteoporosis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Osteoporosis
Interventions
DRUG

Teriparatide

Administered subcutaneously during the Treatment Period

DRUG

Aspara-CA 600 mg

Administered orally throughout the study

DRUG

Alfarol 1.0 µg

Administered orally throughout the study

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01430104 - A Study of Teriparatide in Japanese Osteoporosis Patients | Biotech Hunter | Biotech Hunter